Scarica l'app Stockscreener
162.13
0.35%
-0.57
Pre-mercato:
159.78
-2.35
-1.45%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché AZN Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Astrazeneca Plc Borsa (AZN) Ultime notizie
AstraZeneca Loses Second Suit Against Medicare Drug Price Cuts - Bloomberg Law News
AstraZeneca rallies Friday, outperforms market - MarketWatch
AstraZeneca trips in PD-1 bispecific market after Phase III NSCLC failure - Clinical Trials Arena
Madison Asset Management LLC Buys Shares of 21,310 Astrazeneca Plc $AZN - MarketBeat
Resilient AstraZeneca stock holds firm after oncology trial wins - Ad-hoc-news.de
Resilient AstraZeneca stock steadies after recent US gains - Ad-hoc-news.de
AstraZeneca (AZN) Results Check: EPS Prints Above Forecast on the Day; Market Reaction: The Market Price Advances 3.03% at the CloseEarnings Season Outlook - Vinanet
7,500 Shares in Astrazeneca Plc $AZN Bought by Westport Asset Management Inc. - MarketBeat
AstraZeneca PLC : Goldman Sachs reaffirms its Buy rating - marketscreener.com
Is It Too Late to Buy AstraZeneca PLC (AZN) After 3.0% Rally? GF Value Says Undervalued - GuruFocus
AstraZeneca PLC Stock (AZN) Moved Up by 3.40% on Aug 19: What Signal Does It Send? - TradingKey
AstraZeneca Expands Respiratory Pipeline With New China Trial for Chronic Lung Infections - TipRanks
Rumors of AstraZeneca-Bristol-Myers merger fade; focus shifts to each firm's strengths in cancer and immune diseases. - Pluang
AstraZeneca (AZN) CFO’s share award vests at £114.60 a share - Stock Titan
AstraZeneca Vs. Bristol-Myers Squibb: Who’s The Better Bargain For Investors (NYSE:BMY) - Seeking Alpha
Another disappointment: AstraZeneca halts Phase III lung cancer trial for volrustomig - European Biotechnology Magazine
Is AstraZeneca (LSE:AZN) Becoming the Quiet Anchor of a Jittery London Market? - Kalkine Media
Why Is Large Pharmaceutical Pipelines During Broader Market Uncertainty Active In London Today? - Kalkine Media
AstraZeneca CFO Receives First Vesting Under Long-Term Performance Share Plan - TipRanks
REGAstraZeneca PLCDirector/PDMR Shareholding - TradingView
AstraZeneca PLC : Deutsche Bank reiterates its Sell rating - marketscreener.com
AstraZeneca PLC : UBS reiterates its Buy rating - marketscreener.com
BioMarin Pays $275M Upfront for Alesta to Challenge AstraZeneca in Rare Bone Disease - finance.biggo.com
AstraZeneca rises Tuesday, outperforms market - MarketWatch
AstraZeneca maintains Citi 'buy' rating despite mixed pipeline updates - Proactive financial news
AstraZeneca stock edges higher as Q2 2026 growth and EPS gains offset lung cancer trial setback - AD HOC NEWS
Why Is AstraZeneca (LSE:AZN) Anchoring London's Healthcare Trade Today? - Kalkine Media
AstraZeneca’s win in lung cancer; Sandoz inks a China deal - Yahoo Finance
Did AstraZeneca's (LSE:AZN) Lung Cancer Data Just Reset The Blue-Chip Mood Today? - Kalkine Media
AstraZeneca stock rises on lung cancer trial news - AD HOC NEWS
Can AstraZeneca (LSE:AZN) And GSK (LSE:GSK) Turn Regulatory Review Into Durable Progress? - Kalkine Media
Can Shell (LSE:SHEL) And AstraZeneca (LSE:AZN) Turn Capital Allocation Into Durable Progress? - Kalkine Media
Health Care Down on Growth DoubtsHealth Care Roundup - marketscreener.com
AstraZeneca's Portfolio and Pipeline Support Solid Long-Term Growth - Morningstar
These UK Stocks Are Undervalued After Earnings - Morningstar
AstraZeneca Halts Key Lung-Cancer Trial--But Shares Barely Flinch - Yahoo Finance
AstraZeneca Halts Phase III Lung Cancer Trial as Drug Falls Short Against Keytruda - finance.biggo.com
AstraZeneca abandons lung cancer treatment trial in fresh setback for drugs giant - Yahoo Finance UK
AstraZeneca ditches lung cancer treatment trial - Yahoo Finance UK
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer - BioPharma Dive
UK Shares Start Week Downbeat; AstraZeneca Shares Data from Lung Cancer Trials - marketscreener.com
AstraZeneca stock gains on lung cancer trial news - ad-hoc-news.de
AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies - Benzinga
Market Wrap: EU chip stocks surge on Anthropic's earnings! AstraZeneca halts trials for lung cancer therapy (17.08.2026) - XTB.com
AstraZeneca (AZN) drug delays progression in first-line HER2 lung cancer - Stock Titan
AstraZeneca axes NSCLC trial after bispecific deemed unlikely to best Keytruda - Clinical Trials Arena
AstraZeneca (NYSE: AZN) halts lung trial after survival goals seen unlikely - Stock Titan
Lung cancer trial success puts AstraZeneca (AZN) drug duo in play - Stock Titan
Plato Investment Management Ltd Takes $5.90 Million Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca PLC : JP Morgan remains its Buy rating - marketscreener.com
AstraZeneca halts lung cancer trial in fresh pipeline setback - Proactive financial news
AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review -- Update - marketscreener.com
FTSE 100 Gains Support From Miners, AstraZeneca And Rolls-Royce - DirectorsTalk Interviews
AstraZeneca PLC (AZN) Stock Analysis: Exploring a 36.59% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews
AstraZeneca Stops Cancer Drug Trial as Success Seen Unlikely - Bloomberg.com
AstraZeneca Halts Lung Cancer Trial for Volrustomig; Reports Positive Data for Tagrisso Combo, Enhertu - Yahoo Finance UK
AstraZeneca halts lung trial as two cancer drugs show positive results - marketscreener.com
AstraZeneca (LSE:AZN) Puts Blue-Chip Stocks Under An Earnings-Quality Spotlight - Kalkine Media
AstraZeneca Reports Positive Results with Lung Cancer Drugs - marketscreener.com
AstraZeneca scraps late-stage lung cancer trial after data setback - Investing.com Nigeria
Why is AstraZeneca stock up today? By Investing.com - Investing.com UK
Triple news for AstraZeneca - marketscreener.com
AstraZeneca reports Phase III survival benefit for Tagrisso–Orpathys lung cancer combination - Yahoo Finance UK
AstraZeneca, Daiichi Sankyo's Enhertu Improves Progression-free Survival in Late-stage Lung Cancer Trial - marketscreener.com
AstraZeneca discontinues lung cancer trial of volrustomig - Investing.com Nigeria
AstraZeneca ends one trial; Telecom Plus backs view - marketscreener.com
0.59%
0.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):